Who makes Azithromycin plus piperaquine phosphate?

Azithromycin plus piperaquine phosphate is developed by Papua New Guinea Institute of Medical Research.

What development phase is Azithromycin plus piperaquine phosphate in?

Azithromycin plus piperaquine phosphate is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Azithromycin plus piperaquine phosphate

Papua New Guinea Institute of Medical Research · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Azithromycin plus piperaquine phosphate
Also known as	Sandoz Azithromycin, Sigma-Tau Piperaquine tetraphosphate
Sponsor	Papua New Guinea Institute of Medical Research
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Azithromycin plus piperaquine phosphate CI brief — competitive landscape report
Azithromycin plus piperaquine phosphate updates RSS · CI watch RSS
Papua New Guinea Institute of Medical Research portfolio CI